La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Monte Rosa Therapeutics Gestion
Gestion contrôle des critères 2/4
Monte Rosa Therapeutics' CEO is Markus Warmuth, appointed in Jan 2020, has a tenure of 4.58 years. total yearly compensation is $3.63M, comprised of 17% salary and 83% bonuses, including company stock and options. directly owns 0.68% of the company’s shares, worth $2.02M. The average tenure of the management team and the board of directors is 1.9 years and 3.9 years respectively.
Informations clés
Markus Warmuth
Directeur général
US$3.6m
Rémunération totale
| Pourcentage du salaire du PDG | 17.0% |
| Durée du mandat du directeur général | 4.6yrs |
| Propriété du PDG | 0.7% |
| Durée moyenne d'occupation des postes de direction | 1.9yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 3.9yrs |
Mises à jour récentes de la gestion
Recent updates
Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth
Mar 20
Here's Why We're Watching Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Situation
Sep 29Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?
May 01We're Not Very Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn Rate
Jan 16We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Oct 01Monte Rosa Therapeutics rises 9% after FDA clears application for human trial of lung cancer treatment
Sep 06We're Hopeful That Monte Rosa Therapeutics (NASDAQ:GLUE) Will Use Its Cash Wisely
Jun 17We Think Monte Rosa Therapeutics (NASDAQ:GLUE) Can Afford To Drive Business Growth
Mar 04We're Not Worried About Monte Rosa Therapeutics' (NASDAQ:GLUE) Cash Burn
Sep 24Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$130m |
| Mar 31 2024 | n/a | n/a | -US$135m |
| Dec 31 2023 | US$4m | US$616k | -US$135m |
| Sep 30 2023 | n/a | n/a | -US$133m |
| Jun 30 2023 | n/a | n/a | -US$125m |
| Mar 31 2023 | n/a | n/a | -US$117m |
| Dec 31 2022 | US$4m | US$582k | -US$109m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$94m |
| Mar 31 2022 | n/a | n/a | -US$86m |
| Dec 31 2021 | US$5m | US$525k | -US$74m |
| Sep 30 2021 | n/a | n/a | -US$70m |
| Jun 30 2021 | n/a | n/a | -US$57m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$2m | US$465k | -US$36m |
Rémunération vs marché: Markus's total compensation ($USD3.63M) is above average for companies of similar size in the US market ($USD1.55M).
Rémunération et revenus: Markus's compensation has been consistent with company performance over the past year.
PDG
Markus Warmuth (53 yo)
4.6yrs
Titularisation
US$3,627,130
Compensation
Dr. Markus Warmuth, M.D., serves on Board of Directors of Ventus Therapeutics U.S., Inc. since December 7, 2021. He serves as President, Chief Executive Officer and Director at Monte Rosa Therapeutics, Inc...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 4.6yrs | US$3.63m | 0.68% $ 2.0m | |
| Chief Medical Officer | 3.2yrs | US$1.49m | 0% $ 0 | |
| Chief Operating Officer | 3.4yrs | pas de données | pas de données | |
| Chief Data & Information Officer | less than a year | pas de données | pas de données | |
| Chief Scientific Officer | less than a year | pas de données | pas de données | |
| Senior VP and Head of IR & Strategic Finance | less than a year | pas de données | pas de données | |
| Chief Business & Legal Officer | 2.4yrs | pas de données | pas de données | |
| Senior Vice President of Drug Discovery | 1.4yrs | pas de données | pas de données | |
| Vice President & Corporate Controller | no data | pas de données | 0.023% $ 67.5k |
1.9yrs
Durée moyenne de l'emploi
51yo
Âge moyen
Gestion expérimentée: GLUE's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 4.6yrs | US$3.63m | 0.68% $ 2.0m | |
| Independent Director | 3.7yrs | US$150.88k | 0% $ 0 | |
| Independent Chairman of the Board | 3.9yrs | US$153.38k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$140.88k | 0% $ 0 | |
| Independent Director | 3.9yrs | pas de données | pas de données | |
| Independent Director | 1.1yrs | US$202.10k | 0% $ 0 | |
| Independent Director | 1.4yrs | US$339.56k | 0% $ 0 | |
| Scientific Advisor & Member of Scientific Advisory Board | less than a year | US$1.42m | 0% $ 0 | |
| Independent Director | 4.1yrs | US$140.88k | 0% $ 0 |
3.9yrs
Durée moyenne de l'emploi
55yo
Âge moyen
Conseil d'administration expérimenté: GLUE's board of directors are considered experienced (3.9 years average tenure).